| Sep 6 |
Why Big Pharma is betting on telehealth strategies
|
| Aug 27 |
Why Eli Lilly is 'the Nvidia of GLP-1' weight-loss drugs
|
| Aug 27 |
Hims & Hers Health Post Q2 Earnings: Compounded GLP-1 Ploy Faces New Threats (Rating Downgrade)
|
| Aug 27 |
Walgreens, Hims stocks drop as Lilly rolls out cheap weight-loss drugs (update)
|
| Aug 27 |
Biggest stock movers today: PODD, HIMS, PARA, and more
|
| Aug 27 |
Why Hims & Hers Health Stock Is Falling
|
| Aug 27 |
American Woodmark Reports Downbeat Results, Joins Snowflake And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
|
| Aug 22 |
Hims & Hers: More GLP-1 Uncertainties Ahead, Despite Robust Growth Prospects
|
| Aug 22 |
Hims & Hers wins Buy at Needham despite recent volatility
|
| Aug 21 |
Hims & Hers Health: GLP-1 Is Not The Only Tailwind In This Growth Story
|
